Immunovant CFO Tiago Girao sells $263,014 in company stock By Investing.com

Immunovant, Inc. () Chief Financial Officer Tiago Girao sold 6,798 shares of company common stock on July 23, 2026, totaling approximately $263,014. The transaction comes as IMVT shares trade at $39.41, near their 52-week high of $41.23, following a remarkable 115% return over the past year.

The shares were sold at prices ranging from $38.18 to $39.05 per share, with a weighted average price of $38.69. This transaction was executed to cover tax withholding obligations associated with the vesting and settlement of restricted stock units (RSUs) previously granted to Mr. Girao. The sale was mandated by Immunovant’s policy requiring tax withholding obligations to be funded by a “sell to cover” transaction and was not a discretionary sale by the reporting person.

Following this transaction, Mr. Girao directly holds 240,798 shares of Immunovant common stock. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate. Investors can access comprehensive valuation insights and 10 additional InvestingPro Tips for IMVT, plus detailed Pro Research Reports covering over 1,400 US equities.

In other recent news, Immunovant has garnered attention due to several analyst updates and trial results. H.C. Wainwright raised its price target for Immunovant shares to $40, citing compelling response rates from the company’s Phase 2 rheumatoid arthritis study. The study revealed significant ACR response rates at week 16 in 165 highly refractory RA patients. Meanwhile, BofA Securities increased its price target to $43, driven by a higher peak sales outlook for IMVT-1402, particularly in Graves’ disease and difficult-to-treat rheumatoid arthritis markets. Stifel reiterated its Buy rating with a $49 price target, following Immunovant’s fourth-quarter results and trial data from IMVT-1402, noting high response rates in the open-label Part 1 portion of the study. Additionally, , which includes Immunovant in its portfolio, reported its fourth-quarter earnings for fiscal year 2026. Despite missing earnings per share expectations, Roivant highlighted its robust cash position and strategic product pipeline advancements. These developments have contributed to positive sentiment around Immunovant’s innovative clinical progress.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.